Citi upgrades Genzyme (Nasdaq: GENZ) from Hold to Buy. Price target increased from $80 to $91.

Citi ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE